15
Participants
Start Date
July 7, 2025
Primary Completion Date
August 15, 2026
Study Completion Date
August 15, 2027
Aflibercept 8 mg (VEGF Trap-Eye, BAY86-5321)
Identify patients that have had a previous vitrectomy and have DME that requires anti-VEGF therapy. Then using a treat-extend-stop protocol6,7 that I previously published, treat patients with DME using high dose aflibercept, until the fluid has resolved and then extend the time interval in between treatments for those patients, while maintaining a fluid-free macula.
RECRUITING
Retina Consultants of Orange County, Fullerton
Regeneron Pharmaceuticals
INDUSTRY
Retina Consultants of Orange County
OTHER